ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d)List of Exhibits
|
EXHIBIT NO. |
|
DESCRIPTION |
|
2.1* |
Asset Purchase Agreement, dated October3, 2016, by and |
Schedules omitted to item 601(b)(2)of Regulation S-K. The Company
agrees to furnish supplementally a copy of any omitted schedule
to the SEC upon its request.
* Certain information in this exhibit has been omitted and filed
separately with the Securities and Exchange Commission to a
Confidential Treatment Request submitted to the Securities and
Exchange Commission to Rule24b-2 under the Securities Exchange
Act of 1934, as amended.
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Date: January5, 2017 |
ARALEZ PHARMACEUTICALS INC. |
|
|
By: |
/s/ Eric L. Trachtenberg |
|
|
Eric L. Trachtenberg |
||
|
General Counsel, Chief Compliance Officer and Corporate |
EXHIBITINDEX
|
EXHIBIT NO. |
|
DESCRIPTION |
|
2.1* |
Asset Purchase Agreement, dated October3, 2016, by and |
|
Schedules omitted to item 601(b)(2)of Regulation S-K. The
Company agrees to furnish supplementally a copy of any omitted
schedule to the SEC upon its request.
* Certain information in this exhibit has been omitted and
filed separately with the Securities and Exchange Commission to
a Confidential Treatment Request submitted to the Securities
and Exchange Commission
